



Oxford BioDynamics plc
("Oxford BioDynamics" or the "Company")

**Oxford BioDynamics and Georgetown University Medical Center, Washington, DC
present real-world clinical utility data for the Checkpoint Inhibitor Response Test
(EpiSwitch® CiRT) at ASCO-GI 2025**

- *EpiSwitch CiRT is a first-of-its-kind precision medicine test of high accuracy that predicts a patient's most likely response to Immune Checkpoint Inhibitor (ICI) therapy*
- *Georgetown University Medical Centre, Washington, DC will be presenting CiRT evaluation data on a key cohort of patients with Hepatocellular Carcinoma and Gastrointestinal Tumors*
- *In patients treated with ICI therapy, the CiRT prediction of high probability of response is associated with improved anti-cancer responses, prolonged progression-free survival and significantly better outcomes*
- *The American Society of Clinical Oncology Gastrointestinal Cancers (ASCO-GI) annual meeting is attended by over 4,000 oncologists, oncology care team members and pharma drug developers every year*

Oxford, UK - 23 January 2025- Oxford BioDynamics, Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that Georgetown University Medical Center will be presenting significant data related to the clinical utility of its flagship CiRT clinical assay at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), which is being held January 23 - 25, 2025, at the Moscone Center West in San Francisco, CA.

Dr Aiwa Ruth He, MD, PhD of Georgetown University Medical Center, a board-certified oncologist, and principal investigator of the collaborative program with OBD, and Dr. Mahmoud Ouf, a clinical researcher at Lombardi Cancer Center will present "Evaluation of EpiSwitch in Predicting Immunotherapy Response in Hepatocellular Carcinoma and Gastrointestinal Tumors" on Friday, January 24, 2025.

Liver cancer, particularly hepatocellular carcinoma, is a challenging and deadly disease mainly due to frequent diagnoses at advanced stages when the cancer has already spread or is inoperable, making treatment options limited. Additionally, liver cancer is resistant to many standard therapies, and its aggressive nature means that it can quickly become resistant to even newer targeted treatments or immunotherapies. These factors combined make liver cancer a particularly difficult disease to treat effectively. There is a need for reliable molecular profiling tests, such as EpiSwitch CiRT, that can help identify which class of drugs a patient is likely to respond to.

The presentation showcases that patients with a CiRT HP status (high probability of response) were associated with improved anti-cancer responses, prolonged progression-free survival (PFS), and better outcomes in hepatocellular carcinoma (HCC) and other gastrointestinal (GI) tumors. The mean Progression Free Survival (PFS) for the CiRT HP group was 30.7 months compared to 13.3 months for the CiRT LP group (low probability of response). These findings highlight CiRT's potential to address a critical unmet need for reliable predictive biomarkers in liver and GI cancer treatment.

Dr. Alexandre Akoulitchiev, Chief Scientific Officer of OBD said, "We are excited that Georgetown will be sharing its CiRT evaluation data at the high impact ASCO-GI annual meeting. It is a great opportunity to showcase the real-world clinical utility behind our EpiSwitch CiRT assay in one of the hardest diseases to treat in the world - liver cancer. We look forward to showcasing the clinical advantages of CiRT and its strong predictions of GI cancer patients who might have a robust response to immunotherapy or might benefit instead from other treatment options. We are pleased with the outcomes of this study."

Reference: *Journal of Clinical Oncology*, 43, 2025 (suppl 4; abstr 623)

-Ends-

For more information:

Oxford BioDynamics PLC
Matthew Wakefield, Non-Executive Chairman

+44 (0)1865 518910

Paul Stockdale, CFO

Shore Capital - Nominated Adviser and Joint Broker

Advisory: Stephane Auton / Lucy Bowden

Broking: Fiona Conroy

+44 (0)20 7408 4090

OAK Securities - Joint Broker

Jerry Keen / Henry Clarke / Damion Carruel

+44 (0)203 973 3678

WG Partners - Joint Broker

David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby

+44 (0)20 3705 9330

Vigo Consulting Media / Analyst enquiries for OBD

Rozi Morris

+44 (0)20 7390 0230
obd@vigoconsulting.com

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the [EpiSwitch® PSE](#) (EpiSwitch Prostate Screening test) and [EpiSwitch® CiRT](#) (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or [LinkedIn](#).

About ASCO-GI Symposium

The ASCO-GI Symposium is a crucial meeting for oncologists, focusing on the latest advancements in the treatment and management of gastrointestinal cancers, including colorectal, pancreatic, liver, esophageal, and gastric cancers. The conference provides a platform for professionals to access cutting-edge research, clinical trial data, and emerging therapies. It also facilitates networking and collaboration among global experts, helping oncologists stay current with new treatment protocols and innovative technologies. ASCO-GI enables oncologists to enhance their clinical practice, improve patient outcomes, and contribute to the advancement of the field through knowledge exchange. ASCO-GI is known as the largest gathering of GI oncologists in the world with the annual conference attracting more than 4,000 attendees and over 570 exhibitors.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAPKBBPKBKADB